Imaging Biometrics®, LLC (“IB”), a subsidiary of IQ-AI Limited (LON:IQAI), is pleased to announce that the Montgomery Cancer Center (Montgomery, Alabama, USA), has purchased IB Clinic.
The Montgomery Cancer Center, one of the largest freestanding centers in the USA, will now be able to automatically generate quantitative parameters using IB’s standardised brain tumour imaging protocol for the benefit of patients.
The installation of IB Clinic includes the IB Neuro™ and IB Delta T1 mapping algorithms. These two maps continue to gain acceptance in brain tumour imaging and assessment. Delta T1 maps offer an objective and rapid visual assist for neuro radiologists.
Specifically, the unique maps clearly identify subtle regions of contrast enhancement on routine MR images while, at the same time, eliminate confounding factors such as post-surgical blood products and other artifacts.
Then, after the enhancing region is identified on the Delta T1 maps, IB Neuro’s blood volume maps are used to quantitatively answer what the Board considers is the most important question in neuro oncology today: Is the enhancing region showing tumour or is it an effect due to treatment?
The Directors of the Company accept responsibility for the contents of this announcement.
